Gold Nanoparticles for Targeted Delivery of Chemotherapeutics to Prostate Tumors
Links to Files
Permanent Link
Author/Creator
Author/Creator ORCID
Date
Type of Work
Department
Chemistry & Biochemistry
Program
Chemistry
Citation of Original Publication
Rights
This item may be protected under Title 17 of the U.S. Copyright Law. It is made available by UMBC for non-commercial research and education. For permission to publish or reproduce, please see http://aok.lib.umbc.edu/specoll/repro.php or contact Special Collections at speccoll(at)umbc.edu
Distribution Rights granted to UMBC by the author.
Access limited to the UMBC community. Item may possibly be obtained via Interlibrary Loan thorugh a local library, pending author/copyright holder's permission.
Distribution Rights granted to UMBC by the author.
Access limited to the UMBC community. Item may possibly be obtained via Interlibrary Loan thorugh a local library, pending author/copyright holder's permission.
Subjects
Abstract
The design of novel nanoparticle platforms for targeted and efficient drug delivery is critical for improving cancer nanomedicine. Current treatment strategies for cancer are limited by the nonspecific and highly cytotoxic nature of chemotherapeutic drugs to the body as a whole. Targeted nanoparticles represent a way to delivery chemotherapeutics to treat cancer without the need for high dosing regimens and unwanted off-target cytotoxicity. Dendronized gold nanoparticles have an ideal size that allows for enhanced circulation and can be coated with a poly(propylene imine) (PPI) dendron that confers biocompatibility, active targeting and stimuli-responsive drug release. This work describes the synthesis of a dendronized PPI gold nanoparticle with multifunctional potential for conjugation to chemotherapeutics like doxorubicin, an active targeting antibody fragment, and a gadolinium chelate magnetic resonance imaging contrast imaging agent. The multifunctional nanoparticles here display strong targeted uptake as seen with TEM, strong cytotoxicity against PC3 prostate cancer cells, and have excellent potential as a cancer nanotechnology platform.